Psoriasis
2021 · The Lancet · 2,016 citations
https://doi.org/10.1016/s0140-6736(20)32549-6
C
C.E.M. Griffiths
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
70.9K
Citations
131
h-index
703
i10-index
C.E.M. Griffiths is an academic researcher from Brigham Young University. The author has contributed to research in topics: Psoriasis: Treatment and Pathogenesis & Dermatology and Skin Diseases & Skin Protection and Aging. The author has an h-index of 131, co-authored 1093 publications.
ORCID: 0000-0001-5371-4427Papers by this author
worksIdentification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
2012 · Nature Genetics · 1,038 citations
https://doi.org/10.1038/ng.2467
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
2017 · Journal of the American Academy of Dermatology · 838 citations
https://doi.org/10.1016/j.jaad.2016.11.041
Keratinocytes as initiators of inflammation
1991 · The Lancet · 776 citations
https://doi.org/10.1016/0140-6736(91)92168-2
Keratinocytes as initiators of inflammation
1991 · The Lancet · 776 citations
https://doi.org/10.1016/0140-6736(91)92168-2
Keratinocytes as initiators of inflammation
1991 · The Lancet · 776 citations
https://doi.org/10.1016/0140-6736(91)92168-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat